InsiderTrades.com logo
2024's Must-Watch Stocks!
From Darwin   |   Ad
Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.
[Unlock Your Report Now]
Scott Akamine net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Scott Akamine Biography and Net Worth

Chief Legal Officer and Corporate Secretary of Cerevel Therapeutics

Scott M. Akamine has served as our Chief Legal Officer and Corporate Secretary since May 2021.

Mr. Akamine joined Cerevel Therapeutics from AEON Biopharma, Inc., a privately-held biopharmaceutical company, where he served as general counsel and corporate secretary of overseeing legal and certain administrative functions including business development, corporate governance, intellectual property, and compliance. Prior to AEON, Mr. Akamine was the associate general counsel and interim general counsel at CoreLogic, Inc. and general counsel and corporate secretary at Incipio, LLC. Mr. Akamine also held legal roles of escalating responsibility at Allergan, Inc. until the company was acquired by Actavis plc.

Mr. Akamine began his legal career as a corporate attorney at Latham & Watkins. He earned his B.A. from Chapman University and his J.D. from Pepperdine University School of Law.

What is Scott Akamine's net worth?

The estimated net worth of Scott Akamine is at least $23,064.48 as of December 7th, 2023. Mr. Akamine owns 513 shares of Cerevel Therapeutics stock worth more than $23,064 as of November 17th. This net worth evaluation does not reflect any other assets that Mr. Akamine may own. Additionally, Mr. Akamine receives a salary of $444,740.00 as Chief Legal Officer and Corporate Secretary at Cerevel Therapeutics. Learn More about Scott Akamine's net worth.

How old is Scott Akamine?

Mr. Akamine is currently 39 years old. There are 8 older executives and no younger executives at Cerevel Therapeutics. The oldest executive at Cerevel Therapeutics is Mr. Kenneth A. DiPietro, Chief Human Resources Officer, who is 65 years old. Learn More on Scott Akamine's age.

What is Scott Akamine's salary?

As the Chief Legal Officer and Corporate Secretary of Cerevel Therapeutics Holdings, Inc., Mr. Akamine earns $444,740.00 per year. There are 5 executives that earn more than Mr. Akamine. The highest earning executive at Cerevel Therapeutics is Dr. N. Anthony Coles Jr., M.P.H., Executive Chairman, who commands a salary of $1,140,000.00 per year. Learn More on Scott Akamine's salary.

How do I contact Scott Akamine?

The corporate mailing address for Mr. Akamine and other Cerevel Therapeutics executives is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. Cerevel Therapeutics can also be reached via phone at 844-304-2048 and via email at [email protected]. Learn More on Scott Akamine's contact information.

Has Scott Akamine been buying or selling shares of Cerevel Therapeutics?

Scott Akamine has not been actively trading shares of Cerevel Therapeutics during the last ninety days. Most recently, Scott Akamine sold 10,000 shares of the business's stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $41.37, for a transaction totalling $413,700.00. Following the completion of the sale, the insider now directly owns 513 shares of the company's stock, valued at $21,222.81. Learn More on Scott Akamine's trading history.

Who are Cerevel Therapeutics' active insiders?

Cerevel Therapeutics' insider roster includes Scott Akamine (Chief Legal Officer and Corporate Secretary), Susan Altschuller (CFO), Paul Burgess (Chief Business Development and Strategic Operations Officer), Anthony Coles (Director), Kenneth DiPietro (Insider), Deval Patrick (Director), Ronald Renaud, Jr. (CEO), John Renger (Insider), Ramiro Sanchez (Insider), and Gabrielle Sulzberger (Director). Learn More on Cerevel Therapeutics' active insiders.

Are insiders buying or selling shares of Cerevel Therapeutics?

In the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 236,864 shares worth more than $9,768,056.92. The most recent insider tranaction occured on July, 1st when Director N Anthony Coles sold 25,000 shares worth more than $1,029,500.00. Insiders at Cerevel Therapeutics own 5.1% of the company. Learn More about insider trades at Cerevel Therapeutics.

Information on this page was last updated on 7/1/2024.

Scott Akamine Insider Trading History at Cerevel Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/7/2023Sell10,000$41.37$413,700.00513View SEC Filing Icon  
12/5/2023Sell7,500$35.00$262,500.00513View SEC Filing Icon  
See Full Table

Scott Akamine Buying and Selling Activity at Cerevel Therapeutics

This chart shows Scott Akamine's buying and selling at Cerevel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cerevel Therapeutics Company Overview

Cerevel Therapeutics logo
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $44.96
Low: $44.96
High: $44.96

50 Day Range

MA: $43.67
Low: $40.30
High: $44.96

2 Week Range

Now: $44.96
Low: $19.59
High: $44.99

Volume

N/A

Average Volume

1,709,788 shs

Market Capitalization

$8.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4
2024's Must-Watch Stocks!
From Darwin   |   Ad
Welcome to a year of unparalleled opportunities! Dive into our exclusive guide, "9 Stocks Set to Soar," meticulously selected to elevate your portfolio in 2024. Step into 2024 with confidence and the right assets at your fingertips. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.
[Unlock Your Report Now]